Showing results (1-10 of 117) with videos related to
Sort By:
Pageof 12
Dermatologie (Heidelberg, Germany)|May 7, 2025
[Biomarkers in adjuvant and neoadjuvant treatment of melanoma]Julian Kött, Christoffer GebhardtJournal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|January 29, 2016
Biomarker value and pitfalls of serum S100B in the follow-up of high-risk melanoma patientsChristoffer Gebhardt, Ramtin Lichtenberger, Jochen UtikalOncoimmunology|July 30, 2016
Predictive immune markers in advanced melanoma patients treated with ipilimumabViktor Umansky, Jochen Utikal, Christoffer GebhardtJournal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|March 9, 2023
Status quo and future perspectives of molecular diagnostics in dermatologyChristoffer Gebhardt, Kilian Eyerich, Natalie Garzorz-StarkVaccines|November 10, 2016
The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer ProgressionViktor Umansky, Carolin Blattner, Christoffer Gebhardt, et al.European Journal of Cancer (Oxford, England : 1990)|October 3, 2022
Immune checkpoint blockade for organ-transplant recipients with cancer: A reviewAlessandra Rünger, Dirk Schadendorf, Axel Hauschild, et al.Biochemical Pharmacology|July 19, 2006
S100A8 and S100A9 in inflammation and cancerChristoffer Gebhardt, Julia Németh, Peter Angel, et al.Advances in Medical Sciences|January 18, 2015
New therapeutic options for advanced non-resectable malignant melanomaSimone Stadler, Kasia Weina, Christoffer Gebhardt, et al.Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|September 30, 2014
Myeloid-derived suppressor cells in malignant melanomaViktor Umansky, Alexandra Sevko, Christoffer Gebhardt, et al.Cancer Immunology, Immunotherapy : CII|April 7, 2017
CCR5 in recruitment and activation of myeloid-derived suppressor cells in melanomaViktor Umansky, Carolin Blattner, Christoffer Gebhardt, et al.Pageof 12